First Insights into the Gut Microbiota of Mexican Patients with Celiac Disease and Non-Celiac Gluten Sensitivity

Nutrients

卷:10

Peter Grube-Pagola¹  FranciscoJ. Cabrera-Jorge¹  Hector Vivanco-Cid¹  Xaira Rivera-Gutierrez¹  JoseF. Garcia-Mazcorro¹  Karina Hernandez-Flores¹  Arturo Meixueiro-Daza¹  OrestesDe Jesus Cobos-Quevedo¹  JoseM. Remes-Troche²  ScotE. Dowd³ 

[1] Instituto de Investigaciones Medico Biológicas, Universidad Veracruzana, Calle Agustín de Iturbide, Salvador Díaz Mirón, 91700 Veracruz, México;

[2] Laboratorio de Fisiología Digestiva y Motilidad Gastrointestinal, Instituto de Investigaciones Medico Biológicas, Universidad Veracruzana, Calle Agustín de Iturbide, Salvador Díaz Mirón, 91700 Veracruz, México;

[3] Molecular Research LP, 503 Clovis Rd, Shallowater, TX 79363, USA;

关键词: gluten-related disorders;    celiac disease;    gut microbiota;    gluten-free diet;    Pseudomonas;   

DOI  :  10.3390/nu10111641

来源: DOAJ

【 摘 要 】

Gluten-related disorders (GRDs) are common chronic enteropathies and increasing evidence suggests an involvement of the gut microbiota. We examined the gut microbiota in Mexican people afflicted with GRDs. Ultra-high-throughput 16S marker sequencing was used to deeply describe the duodenal and fecal microbiota of patients with celiac disease (CD, n = 6), non-celiac gluten sensitivity (NCGS, n = 12), and healthy subjects (n = 12) from our local area. Additionally, we also investigated the changes in gut microbiota after four weeks on a gluten-free diet (GFD) in a subset of patients from whom paired samples were available. Despite a high inter-individual variability, significant differences in various microbial populations were identified. The linear discriminant analysis (LDA) effect size (LEfSe) method revealed that the genus Actinobacillus and the family Ruminococcaceae were higher in the duodenal and fecal microbiota of NCGS patients, respectively, while Novispirillum was higher in the duodenum of CD patients (p < 0.05, LDA score > 3.5). Interestingly, paired samples from NCGS patients showed a significant difference in duodenal Pseudomonas between the baseline period (median: 1.3%; min/max: 0.47⁻6.8%) and the period after four weeks on GFD (14.8%; 2.3⁻38.5%, p < 0.01, Wilcoxon signed-rank test). These results encourage more research on GRDs in México.

【 授权许可】

Unknown